Portfolio company
Achilles Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
The company provides no products as it is currently undergoing a solvent liquidation process to pay creditors and distribute remaining assets to shareholders.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Atreca
This biotechnology firm developed antibody-based immunotherapies for cancer and malaria, targeting healthcare providers and patients, before initiating liquidation and selling its assets in 2024.
Athersys
Athersys develops regenerative stem cell therapies to treat patients with neurological, inflammatory, and cardiovascular conditions, primarily through its proprietary off-the-shelf MultiStem cell platform.
Aclaris Therapeutics
This company develops drug candidates for patients with immuno-inflammatory diseases and provides drug discovery services to pharmaceutical and biotechnology partners.
Autolus
Autolus develops programmed T-cell therapies for patients with cancer and autoimmune diseases, including an approved treatment for adult B-cell acute lymphoblastic leukaemia.
Autolus Therapeutics
This company develops programmed T-cell therapies for patients with cancer and autoimmune diseases.
Akribion Therapeutics
The company develops RNA-guided nuclease technology for programmable cell depletion to treat cancer and autoimmune diseases for healthcare providers and patients.
Rubedo Life Sciences
This company develops small-molecule therapeutics and anti-ageing skin care products for patients with age-related diseases and consumers seeking skin rejuvenation.
Tivic Health
The company develops immunotherapeutic drugs and biomanufacturing services for patients with radiation injury, cancer and age-related immune dysfunction.